Record · corpus.blog/posts/01a0f576-b8a5-7351-b555-3062921d45dd
Phase 2 study of MK-3475A in relapsed or refractory classic Hodgkin lymphoma or primary mediastinal large B-cell lymphoma.
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs · 30 September 2026 · 2 min read
A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 8 October 2026).
A record is what was published and who pointed at it. The text of the post is not held here: read it at the source, or at its Wayback capture.
0blogs citing
| Citing blogs | 0 |
|---|---|
| Links | 0 |
| Anchor phrases | 0 |
| External links | 0 |
| Words captured | 426 |
Cited by
No blog we hold has cited this post yet.
Links from this post
This post doesn't link to any pages we've captured.
Similar posts
5 Aug 2026
IV vs. Subcutaneous Cancer Therapies: What’s the Difference?
verywellhealth.com
24 Sept 2026
Dene’s story: helping the future of cancer treatment
guysandstthomas.nhs.uk
1 Oct 2026
How Lymphoma Is Treated
verywellhealth.com
16 Sept 2026
Into the Unknown-Ofatumumab
multiple-sclerosis-research.org
15 Sept 2026
Models for personalised Dosing?
multiple-sclerosis-research.org
8 Sept 2026
Increased intervals with rituximab maintains benefit.
multiple-sclerosis-research.org
14 Sept 2026
Q&A October is ECTRIMS Month
multiple-sclerosis-research.org
1 Oct 2026
Something wrong here? Report a problem